China State FDA Grants Simcere Record Fast-track Approval To Market Generic Relenza
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - Nanjing-based Simcere announced during the Chinese New Year celebration that the company received approval from China's State FDA to manufacture and market a generic version of GlaxoSmithKline's antiviral Relenza (zanamivir)
You may also be interested in...
China Leads Pharmaceutical Growth In 2009: Asia Pharma R&D Leaders
SHANGHAI - While China's most influential meeting - the eleventh National People's Congress of China - prepares to open its third session in Beijng March 5, pharma R&D leaders gathered in Shanghai to discuss the future of the pharmaceutical industry
China Leads Pharmaceutical Growth In 2009: Asia Pharma R&D Leaders
SHANGHAI - While China's most influential meeting - the eleventh National People's Congress of China - prepares to open its third session in Beijng March 5, pharma R&D leaders gathered in Shanghai to discuss the future of the pharmaceutical industry
Did The World Health Organization Overreact To The Threat Of A/H1N1?
HONG KONG - A year after the first cases of the A/H1N1 influenza surfaced in Mexico and the U.S., the World Health Organization is facing accusations that it overreacted to the threat and pushed too hard for a rapidly available vaccine